Yilian Biopharmaceuticals

MediLink Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for oncology. The company's core technology is the proprietary TMALIN (Tumor Microenvironment Activable Linker-payload) platform, designed to enhance the therapeutic window and safety profile of ADCs by leveraging tumor microenvironment-specific activation. MediLink has rapidly advanced several candidates into clinical trials, including YL201 (targeting B7-H3) and YL202 (targeting HER3), the latter of which is being co-developed with BioNTech. The company has also secured a significant licensing agreement with Roche for its c-Met targeting ADC, YL211. Headquartered in Suzhou, China, MediLink maintains a global presence with research facilities in Shanghai and the United States.